1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  05/18 04:00:01 pm EDT
308.49 USD   -7.13%
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:40 PM
CI
05/10Dexcom Announces Upcoming Conference Presentations
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

DEXCOM INC : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

01/10/2022 | 08:03am EDT

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

In connection with remarks to be made at the J.P. Morgan Virtual 40th Annual Healthcare Conference on Monday, January 10, 2022, beginning at 10:30 a.m. (Eastern Time), DexCom, Inc. ("DexCom") Chairman, President and Chief Executive Officer Kevin Sayer will report that preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 is expected to be approximately $698 million, an increase of 23% over the fourth quarter of 2020. For fiscal 2021, total preliminary, unaudited revenue is expected to be approximately $2.448 billion, an increase of more than 27% over 2020.

Finally, Mr. Sayer will provide DexCom's initial financial outlook for fiscal year 2022, including an anticipated range for total revenue of $2.82 billion to $2.94 billion.

The fourth quarter and fiscal year 2021 preliminary unaudited financial results contained in Mr. Sayer's presentation and in this report are subject to finalization in connection with the preparation of DexCom's Annual Report on Form 10-K for the twelve months ended December 31, 2021. This report contains, and Mr. Sayer's presentation on January 10, 2022 will contain, forward-looking statements concerning DexCom's or its management's intentions, beliefs, expectations and strategies for the future, including those related to DexCom's preliminary, unaudited revenue for the fourth quarter and the full fiscal year 2021, estimated revenue for fiscal 2022. Because such statements deal with future events, they are subject to various risks and uncertainties. The risks and uncertainties that may cause actual results to differ materially from DexCom's current expectations are more fully described in DexCom's Annual Report on Form 10-K for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on February 11, 2021, its most recent Quarterly Report on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on October 28, 2021, and its other reports, each as filed with the Securities and Exchange Commission. All forward-looking statements and reasons why results might differ included in this Current Report are made as of the date of this Current Report, based on information currently available to DexCom. Should one or more of these risks or uncertainties materialize, or should any of DexCom's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. DexCom undertakes no obligation to publicly update or revise any forward-looking statements or reasons why results might differ.

In connection with Mr. Sayer's presentation, on January 10, 2022, DexCom issued a press release announcing preliminary, unaudited revenue for the fourth quarter of 2021 and fiscal year 2021, initial financial outlook for fiscal year 2022, and certain other information, which is attached here as Exhibit 99.01.

The information in this Item 2.02, including Exhibit 99.01 hereto, is furnished pursuant to Item 2.02 of Form 8-K, and is not deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of DexCom under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

ITEM 8.01. OTHER EVENTS.

In connection with his remarks to be made at the J.P. Morgan Virtual 40th Annual Healthcare Conference Mr. Sayer also presented clinical data on DexCom's next generation interoperable CGM, drawn from the company's U.S. pivotal trial, reporting summary mean absolute relative difference (MARD) as 8.2% in adults and 8.1% in pediatrics.

--------------------------------------------------------------------------------

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.



(d) Exhibits.



Number                                   Description

99.01        Press release dated January 10, 2022 announcing the financial results
           for the quarter ended December 31, 2021 and certain other information.


104        Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about DEXCOM, INC.
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2..
CI
05/10Dexcom Announces Upcoming Conference Presentations
BU
04/29Raymond James Adjusts DexCom's Price Target to $486 From $538, Keeps Outperform Rating
MT
04/29Morgan Stanley Adjusts Price Target for DexCom to $492 From $514, Maintains Equalweigh..
MT
04/29SVB Leerink Adjusts DexCom's Price Target to $500 From $565, Keeps Outperform Rating
MT
04/29Piper Sandler Adjusts DexCom's Price Target to $480 From $725, Reiterates Overweight Ra..
MT
04/28DEXCOM : Reports First Quarter 2022 Financial Results - Form 8-K
PU
04/28DEXCOM INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
04/28TRANSCRIPT : DexCom, Inc., Q1 2022 Earnings Call, Apr 28, 2022
CI
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations